Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- Written by PR Newswire
BEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and...
Read more: Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the...














